Folgen
Maria Frantzi
Maria Frantzi
Mosaiques diagnostics
Bestätigte E-Mail-Adresse bei mosaiques-diagnostics.com
Titel
Zitiert von
Zitiert von
Jahr
Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development
M Frantzi, A Bhat, A Latosinska
Clinical and translational medicine 3 (1), 1-22, 2014
1392014
Profilin 1 is a potential biomarker for bladder cancer aggressiveness
J Zoidakis, M Makridakis, PG Zerefos, V Bitsika, S Esteban, M Frantzi, ...
Molecular & cellular proteomics 11 (4), 2012
1212012
Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center StudyDevelopment of Urinary Biomarker Panels for Bladder Cancer
M Frantzi, KE Van Kessel, EC Zwarthoff, M Marquez, M Rava, N Malats, ...
Clinical Cancer Research 22 (16), 4077-4086, 2016
902016
Developing proteomic biomarkers for bladder cancer: towards clinical application
M Frantzi, A Latosinska, L Flühe, MC Hupe, E Critselis, MW Kramer, ...
Nature Reviews Urology 12 (6), 317-330, 2015
742015
Discovery and validation of urinary biomarkers for detection of renal cell carcinoma
M Frantzi, J Metzger, RE Banks, H Husi, J Klein, M Dakna, W Mullen, ...
Journal of proteomics 98, 44-58, 2014
652014
Proteomics and metabolomics for AKI diagnosis
D Marx, J Metzger, M Pejchinovski, RB Gil, M Frantzi, A Latosinska, ...
Seminars in nephrology 38 (1), 63-87, 2018
632018
Proteomics biomarkers for solid tumors: Current status and future prospects
I Belczacka, A Latosinska, J Metzger, D Marx, A Vlahou, H Mischak, ...
Mass spectrometry reviews 38 (1), 49-78, 2019
622019
Peptidomics and proteomics based on CE‐MS as a robust tool in clinical application: The past, the present, and the future
A Latosinska, J Siwy, H Mischak, M Frantzi
Electrophoresis 40 (18-19), 2294-2308, 2019
602019
Biomarkers for bladder cancer aggressiveness
M Frantzi, M Makridakis, A Vlahou
Current opinion in urology 22 (5), 390-396, 2012
432012
Proteomics in drug development: the dawn of a new era?
M Frantzi, A Latosinska, H Mischak
PROTEOMICS–Clinical Applications 13 (2), 1800087, 2019
422019
Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: focus on bladder cancer
A Latosinska, M Frantzi, A Vlahou, H Mischak
Proteomics–Clinical Applications 7 (11-12), 779-793, 2013
372013
Urinary CE-MS peptide marker pattern for detection of solid tumors
I Belczacka, A Latosinska, J Siwy, J Metzger, AS Merseburger, H Mischak, ...
Scientific reports 8 (1), 1-11, 2018
302018
Clinical proteomics for precision medicine: the bladder cancer case
A Latosinska, M Frantzi, A Vlahou, AS Merseburger, H Mischak
PROTEOMICS–Clinical Applications 12 (2), 1700074, 2018
282018
Proteome‐based classification of Nonmuscle Invasive Bladder Cancer
R Stroggilos, M Mokou, A Latosinska, M Makridakis, V Lygirou, ...
International Journal of Cancer 146 (1), 281-294, 2020
242020
Proteomics analysis of bladder cancer invasion: targeting EIF3D for therapeutic intervention
A Latosinska, M Mokou, M Makridakis, W Mullen, J Zoidakis, V Lygirou, ...
Oncotarget 8 (41), 69435, 2017
232017
CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer
M Frantzi, E Gomez Gomez, A Blanca Pedregosa, J Valero Rosa, ...
British journal of cancer 120 (12), 1120-1128, 2019
222019
Ten years of proteomics in bladder cancer: progress and future directions
M Frantzi, A Vlahou
Bladder Cancer 3 (1), 1-18, 2017
212017
IMAC fractionation in combination with LC–MS reveals H2B and NIF-1 peptides as potential bladder cancer biomarkers
M Frantzi, J Zoidakis, T Papadopoulos, P Zürbig, I Katafigiotis, ...
Journal of proteome research 12 (9), 3969-3979, 2013
212013
Clinical proteomics: Closing the gap from discovery to implementation
M Frantzi, A Latosinska, G Kontostathi, H Mischak
Proteomics 18 (14), 1700463, 2018
202018
Silencing of Profilin-1 suppresses cell adhesion and tumor growth via predicted alterations in integrin and Ca2+ signaling in T24M-based bladder cancer models
M Frantzi, Z Klimou, M Makridakis, J Zoidakis, A Latosinska, DM Borras, ...
Oncotarget 7 (43), 70750, 2016
202016
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20